Ernexa Therapeutics adds monthly cash compensation for its CFO, Mark J. Keeley
Ernexa Therapeutics added monthly cash compensation to the consulting agreement of its CFO, Mark J. Keeley, effective November 9, 2026. According to the Form 8-K filed with the SEC on November 19, 2026, the amendment sets $5,000 per month, payable on the last day of each month and prorated for November 2026. The existing equity-based compensation and all other terms of the agreement remain unchanged.
In 35 seconds
- The amendment to Mark J. Keeley's consulting agreement adds cash compensation effective November 9, 2026.
- The payment is $5,000 per month, on the last day of each month and prorated for November 2026.
- Equity-based compensation and the rest of the agreement's terms are unchanged.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.